Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer

• Published in: The Journal of nuclear medicine (1978) Vol. 53; no. 11; pp. 1670 - 1675
• Main Authors: Saylor, Philip J, Mahmood, Umar, Kunawudhi, Anchisa, Smith, Matthew R, Palmer, Edwin L, Michaelson, M Dror
• Format: Journal Article
• Language: English
• Published: United States 01.11.2012
• Subjects: Biomarkers, Tumor - metabolism; Bone and Bones - diagnostic imaging; Bone Neoplasms - diagnostic imaging; Bone Neoplasms - drug therapy; Bone Neoplasms - secondary; Humans; Indoles - pharmacology; Indoles - therapeutic use; Male; Molecular Targeted Therapy - methods; Orchiectomy; Prostate-Specific Antigen - metabolism; Prostatic Neoplasms - pathology; Prostatic Neoplasms - surgery; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Protein-Tyrosine Kinases - antagonists & inhibitors; Pyrroles - pharmacology; Pyrroles - therapeutic use; Radionuclide Imaging; Sunitinib; Technetium Tc 99m Medronate; Tomography, X-Ray Computed; Treatment Failure

One of the central unanswered questions in prostate cancer research is the significance of tyrosine kinase inhibitor (TKI)-induced improvements in (99m)Tc-methylene diphosphonate ((99m)Tc-MDP) bone scans. Multitargeted tyrosine kinase inhibition has recently shown promise in the management of castra...